TLRY · Tilray Brands, Inc.
Market Cap
$414.06M
Shares
136.20M
Volume · Oct 19
2.55M
Avg daily vol (3M)
4.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.03
Open$3.05
Day$3.00–3.07
52W close$3.03–15.70
Avg vol 30d4.1M
Short int18.8M · 13.8% float · 5.2d
Short vol55%
Last earningsOct 8, 2026
DataJan 2020–Oct 2026
Filing10-Q · Oct 8
Up next
Next earnings call
Dec 10, 2026
Est · unconfirmed
· in 7 wks
filed Oct 8, 2026
call held Jul 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$963.10M
Trailing 12 months
Net income (TTM)
−$164.22M
Trailing 12 months
Revenue growth YoY
+22.7%
Year over year
Operating margin
-9.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$91.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
13.8%
Latest settlement · 5.2 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q4 FY26 earnings call · Jul 28, 2026
Q4 FY26
TL;DR. Tilray delivered record FY2026 revenue of $915.5 million (up 11%) and record adjusted EBITDA of $61.1 million, while reducing net debt to ~$0.7 million; the company also issued FY2027 adjusted EBITDA guidance of $68–$75 million, representing double-digit growth, alongside international cannabis revenue growth of 34% and the BrewDog acquisition.
Bullish
- + Delivered record FY2026 net revenue of $915.5 million, up 11% year-over-year, and raised FY2027 adjusted EBITDA guidance to $68–$75 million (double-digit growth)
- + Record FY2026 adjusted EBITDA of $61.1 million, up 11% year-over-year
Bearish
- − International cannabis revenue was impacted by approximately $21 million of price compression during the year, flowing through to gross profit
- − Canadian medical cannabis revenue declined 5% to $23.7 million due to Veterans Affairs reimbursement changes, expected to reduce FY2027 revenue by ~$4 million per year
- − Wholesale cannabis revenue decreased 60% to $7.3 million
- − Net loss of $105.2 million for FY2026, with full-year GAAP results still loss-making despite adjusted EBITDA growth
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−47%
below
Price vs 50-day avg
−27%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−54%
trailing
YTD return
−66%
this year
Relative strength
−62%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
26 of 240 funds reported for Sep 30 · net +70.6K sh shares · +4 new
Insider flow
Accumulating
Net +$69.2K over 90 days · 0% sells
Short interest
Falling
13.80% of float · ▼ -3.2% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
240 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+11%
Y/Y
Gross margin
28%
contracting
EPS growth
+96%
Y/Y
Free cash flow
$-113.8M
Balance sheet
$96.8M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Oct 8, 2026
Adjusted EBITDA
· fiscal year ending May 31, 2027
Non-GAAP
Maintained
$68M – $75M
Jul 28, 2026
$68M – $75M
changed to
Oct 8, 2026
$68M – $75M
Prior guidance
period ended
· from the 8-K filed Apr 1, 2026
Adjusted EBITDA
· fiscal year ended May 31, 2026
$62M – $72M
Guided vs delivered
· last 1 settled
Net revenue
by the end of fiscal 2024
guided $4B
$788.94M
Miss −80.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−47%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
26 of 240 funds reported for Sep 30 · net +70.6K sh shares · +4 new
Insider flow
Accumulating
Net +$69.2K over 90 days · 0% sells
Short interest
Falling
13.80% of float · ▼ -3.2% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
240 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $3 · 0%
Range high $16
vs 200-day avg -47%
vs 50-day avg -27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted cash operating income (loss) non-GAAP | $1.17M | three months ended August 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating income (loss) -24.05M
+0K Change in fair value of contingent consideration
+18.64M Amortization
+6.58M Stock-based compensation
= Adjusted cash operating income (loss) 1.17M
|
|||
| Adjusted EBITDA non-GAAP | $9.2M | first quarter | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) -40.03M
+1.73M Income tax expense (recovery), net
+6.48M Interest expense, net
+7.77M Non-operating expense (income), net
+18.64M Amortization
+6.58M Stock-based compensation
+0K Change in fair value of contingent consideration
+0K Project 420 business optimization
+787K Litigation costs, net of recoveries
+2.45M Restructuring costs
+4.8M Transaction costs, net
= Adjusted EBITDA 9.21M
|
|||
| Adjusted free cash flow non-GAAP | -$23.42M | three months ended August 31, 2026 | — |
| Adjusted net income (loss) non-GAAP | -$2.99M | three months ended August 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss attributable to stockholders of Tilray Brands, Inc. -43.14M
+7.77M Non-operating expense (income), net
+18.64M Amortization
+6.58M Stock-based compensation
-2.34M Deferred income tax expense (benefits), net
+1.47M Accretion of convertible debt discount
+0K Change in fair value of contingent consideration
+0K Project 420 business optimization
+787K Litigation costs, net of recoveries
+2.45M Restructuring costs
+4.8M Transaction costs, net
= Adjusted net income (loss) -2.99M
|
|||
| Adjusted net loss non-GAAP | $3M | first quarter | — |
| adjusted net loss per share or adjusted EPS non-GAAP | $0.02 | first quarter | — |
| Beverage gross margin | 41% | three months ended August 31, 2026 | — |
| Cannabis gross margin | 39% | three months ended August 31, 2026 | — |
| cash, restricted cash and marketable securities non-GAAP | $221.4M | end of the first quarter | — |
| Distribution gross margin | 11% | three months ended August 31, 2026 | — |
| Distribution revenue | 84.27M | the three months ended August 31, 2026 filing | — |
| Free cash flow | -$27.45M | three months ended August 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash used in operating activities -16.54M
-10.91M Less: investments in capital and intangible assets, net
= Free cash flow -27.45M
|
|||
| Net beverage revenue | 101.5M | the three months ended August 31, 2026 filing | — |
| Net cannabis revenue | 56.11M | the three months ended August 31, 2026 filing | — |
| Wellness gross margin | 29% | three months ended August 31, 2026 | — |
| Wellness revenue | 15.28M | the three months ended August 31, 2026 filing | — |
| Adjusted gross profit (excluding PPA step-up) non-GAAP | 262.59M | For the year ended May 31, 2026 filing | — |
| brew pubs operated | 18 | fiscal 2026 filing | — |
| Cannabis adjusted gross margin (excluding PPA step-up) non-GAAP | 40% | For the year ended May 31, 2026 filing | — |
| Distributor shipping locations | 975 | fiscal 2026 filing | — |
| Operating cash flow excluding changes in working capital non-GAAP | $18.2M | fiscal year 2026 filing | — |
| Total adjusted gross margin (excluding PPA step-up) non-GAAP | 29% | For the year ended May 31, 2026 filing | — |
| Transaction costs (income), net | 6.3M | the year ended May 31, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TLRY
this stock
Tilray Brands, Inc.
|
$414.06M | -66.4% | +11.5% | — | 13.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$62.84B | +25.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.52B | +2.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$48.36B | +32.4% | +4.3% | 68.0 | 2.6% |
|
HLN
Haleon plc
|
$44.55B | +0.3% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TLRY | -9.8% | -25.7% | -53.8% | -19.2% | -66.5% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -8.3% | -24.8% | -61.5% | -19.7% | -78.9% |
Key facts
CIK
1731348
CUSIP
88688T209
13F (30d)
24 filings
24 filers
Visit website
Investor relations